Reid Whitlock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reid Whitlock has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Navdeep Tangri
Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada
13 shared publications Navdeep Tangri
Internal Medicine University of Manitoba College of Medicine Winnipeg Manitoba Canada
11 shared publications- Claudio Rigatto
Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
9 shared publications Paul Komenda
8 shared publications- Clara Bohm
Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
7 shared publications - David Collister
Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, Canada
7 shared publications
Latest Publications
- Open Access
- 13 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11320-11327
Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
Aims: While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis). Given similarities in pathophysiology between CKD in T1DM and T2DM, we conducted a systematic review and meta‐analysis evaluating sodium–glucose cotransporter‐2 inhibitors (SGLT‐2is), mineralocorticoid receptor antagonists (MRAs) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on kidney function, albuminuria and safety outcomes. Materials and Methods: We searched Medline, EMBASE, Cochrane CENTRAL, CINAHL, Global Health, LILACS and Scopus from inception until 11 April 2025, for randomised controlled trials (RCTs) evaluating RASi, MRAs, GLP‐1RAs and SGLT‐2is on change in urine albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in adults (age ≥ 18) with T1DM. Results: A total of 7151 unique records were identified and 41 RCTs were included in the meta‐analysis. No RCTs evaluating nsMRAs or MRAs met our inclusion criteria. Treatment with SGLT‐2i or RASi was associated with a 45% reduction in UACR versus placebo (GMR = 0.55; 95% CI: 0.32–0.94). No difference in the annual rate of eGFR change was observed across drug classes compared to placebo (mean difference 1.16 mL/min/1.73 m 2 /year; 95% CI: −0.38 to 2.70). Treatment was associated with a higher risk of hypoglycaemia (RR = 1.03; 95% CI: 1.01–1.05) and DKA (RR = 1.97; 95% CI: 1.33–2.93). Conclusions: In patients with T1DM, the pooled analysis showed a reduction in UACR overall, but that this appeared to be driven predominantly by the SGLT‐2i studies, with limited and non‐significant evidence in the RAS inhibitor subgroup. Dedicated RCTs in the T1DM population could help establish the efficacy and safety of these different drug classes. Trial Registration: PROSPERO registration: CRD420261352699.
- 13 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11320-11327
Open AccessEffects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
Aims: While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis). Given similarities in pathophysiology between CKD in T1DM and T2DM, we conducted a systematic review and meta‐analysis evaluating sodium–glucose cotransporter‐2 inhibitors (SGLT‐2is), mineralocorticoid receptor antagonists (MRAs) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on kidney function, albuminuria and safety outcomes. Materials and Methods: We searched Medline, EMBASE, Cochrane CENTRAL, CINAHL, Global Health, LILACS and Scopus from inception until 11 April 2025, for randomised controlled trials (RCTs) evaluating RASi, MRAs, GLP‐1RAs and SGLT‐2is on change in urine albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in adults (age ≥ 18) with T1DM. Results: A total of 7151 unique records were identified and 41 RCTs were included in the meta‐analysis. No RCTs evaluating nsMRAs or MRAs met our inclusion criteria. Treatment with SGLT‐2i or RASi was associated with a 45% reduction in UACR versus placebo (GMR = 0.55; 95% CI: 0.32–0.94). No difference in the annual rate of eGFR change was observed across drug classes compared to placebo (mean difference 1.16 mL/min/1.73 m 2 /year; 95% CI: −0.38 to 2.70). Treatment was associated with a higher risk of hypoglycaemia (RR = 1.03; 95% CI: 1.01–1.05) and DKA (RR = 1.97; 95% CI: 1.33–2.93). Conclusions: In patients with T1DM, the pooled analysis showed a reduction in UACR overall, but that this appeared to be driven predominantly by the SGLT‐2i studies, with limited and non‐significant evidence in the RAS inhibitor subgroup. Dedicated RCTs in the T1DM population could help establish the efficacy and safety of these different drug classes. Trial Registration: PROSPERO registration: CRD420261352699.
- Open Access
- 15 July 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (9) , 1251-1268
Trajectory of Kidney Function in T1D over Time: A Scoping Review
Type 1 diabetes (T1D) is associated with chronic kidney disease (CKD) and major adverse cardiovascular events (MACE). Contemporary data on the natural history of kidney function decline and the effect of therapies on slowing disease progression in T1D-related CKD are limited. We conducted a scoping review to describe the natural trajectory of kidney function and its effects in individuals with T1D in the USA. In our scoping review of observational studies and grey literature, we searched EMBASE (Ovid), Cumulative Index to Nursing and Allied Health Literature [CINAHL; Elton B. Stephens Company (EBSCO)], MEDLINE (Ovid), Scopus (Elsevier), Global Health (Ovid), and the Food and Drug Administration from inception to 25 April 2025. The study population included adults (age ≥ 18 years) with T1D in the USA. Our outcomes were change in estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), MACE (myocardial infarction, ischemic stroke, cardiovascular death, unstable angina, or heart failure hospitalization), and healthcare resource use (HCRU). We screened 6437 abstracts and selected 22 texts that matched our criteria. In one cohort, more than 50.0% of individuals with T1D developed moderately increased albuminuria (UACR > 30-299 mg/g) after 20 years and two cohort studies in T1D observed a progressive annual eGFR decline of 3 mL/min/1.73 m2. Five cohort studies found higher proportions of individuals with T1D experienced MACE or kidney failure versus those without T1D. Cross-sectional studies estimated total annual cost of HCRU in the USA at $17-27.8 billion for those with T1D, with annual per-patient costs ranging from $73,534-$112,833 for kidney failure and $40,889-$86,417 for components of MACE. T1D is associated with a high burden of CKD, MACE, and healthcare costs. A clearer understanding of the trajectory of kidney function decline in T1D would help providers and policymakers understand the impact potential therapies to treat T1D-related CKD may have on reducing the risk of kidney failure, MACE, and HCRU.
- 15 July 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (9) , 1251-1268
Open AccessTrajectory of Kidney Function in T1D over Time: A Scoping Review
Type 1 diabetes (T1D) is associated with chronic kidney disease (CKD) and major adverse cardiovascular events (MACE). Contemporary data on the natural history of kidney function decline and the effect of therapies on slowing disease progression in T1D-related CKD are limited. We conducted a scoping review to describe the natural trajectory of kidney function and its effects in individuals with T1D in the USA. In our scoping review of observational studies and grey literature, we searched EMBASE (Ovid), Cumulative Index to Nursing and Allied Health Literature [CINAHL; Elton B. Stephens Company (EBSCO)], MEDLINE (Ovid), Scopus (Elsevier), Global Health (Ovid), and the Food and Drug Administration from inception to 25 April 2025. The study population included adults (age ≥ 18 years) with T1D in the USA. Our outcomes were change in estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), MACE (myocardial infarction, ischemic stroke, cardiovascular death, unstable angina, or heart failure hospitalization), and healthcare resource use (HCRU). We screened 6437 abstracts and selected 22 texts that matched our criteria. In one cohort, more than 50.0% of individuals with T1D developed moderately increased albuminuria (UACR > 30-299 mg/g) after 20 years and two cohort studies in T1D observed a progressive annual eGFR decline of 3 mL/min/1.73 m2. Five cohort studies found higher proportions of individuals with T1D experienced MACE or kidney failure versus those without T1D. Cross-sectional studies estimated total annual cost of HCRU in the USA at $17-27.8 billion for those with T1D, with annual per-patient costs ranging from $73,534-$112,833 for kidney failure and $40,889-$86,417 for components of MACE. T1D is associated with a high burden of CKD, MACE, and healthcare costs. A clearer understanding of the trajectory of kidney function decline in T1D would help providers and policymakers understand the impact potential therapies to treat T1D-related CKD may have on reducing the risk of kidney failure, MACE, and HCRU.
- Open Access
- 10 March 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (5) , 101317
A Prospective, Multicenter, Open-Label Assessment of Efficacy and Safety of the Quanta Dialysis System for Home Hemodialysis
- 10 March 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (5) , 101317
Open AccessA Prospective, Multicenter, Open-Label Assessment of Efficacy and Safety of the Quanta Dialysis System for Home Hemodialysis
- Open Access
- 17 January 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Randomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research Protocol
Introduction: People with hemodialysis-dependent kidney failure experience significantly higher cardiovascular (CV) morbidity, mortality, symptom burden, and cognitive impairment compared to the general population. Hemodialysis-induced ischemia contributes to myocardial stunning, which worsens CV outcomes. Intradialytic cycling has the potential to mitigate cardiac stunning, but its effects have not been assessed in randomized controlled trials (RCTs). Methods: This multicenter RCT evaluates the impact of 12 weeks of intradialytic cycling on hemodialysis-induced myocardial stunning. The study will recruit 160 adults (80 intervention and 80 control) receiving maintenance hemodialysis at five Canadian centers and one Australian center. Outcome assessments are conducted at baseline, 12 weeks, and 16 weeks. An intervention implementation process evaluation is part of this study. Outcomes: The primary outcome is change in number of regional wall motion abnormalities (RWMAs) at peak hemodialysis stress from baseline to 12 weeks. Secondary outcomes include changes in cognitive function, hemodialysis recovery time, and symptom burden. Statistical Analysis: Change in number of RWMAs at peak hemodialysis stress from baseline to 12 weeks are compared between study groups using an independent 2-tailed t test and using a Poisson generalized linear mixed model with study group as a fixed effect, and time and mean ultrafiltration rate as random effects. Conclusion: Compared with standard care, we anticipate that intradialytic cycling will decrease myocardial stunning, resulting in improved symptom burden, and functional and cognitive status. This trial provides critical evidence regarding the benefits and feasibility of exercise during hemodialysis, potentially informing clinical practice, and guidelines for hemodialysis care. Trial registration number: NCT04877041
- 17 January 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Open AccessRandomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research Protocol
Introduction: People with hemodialysis-dependent kidney failure experience significantly higher cardiovascular (CV) morbidity, mortality, symptom burden, and cognitive impairment compared to the general population. Hemodialysis-induced ischemia contributes to myocardial stunning, which worsens CV outcomes. Intradialytic cycling has the potential to mitigate cardiac stunning, but its effects have not been assessed in randomized controlled trials (RCTs). Methods: This multicenter RCT evaluates the impact of 12 weeks of intradialytic cycling on hemodialysis-induced myocardial stunning. The study will recruit 160 adults (80 intervention and 80 control) receiving maintenance hemodialysis at five Canadian centers and one Australian center. Outcome assessments are conducted at baseline, 12 weeks, and 16 weeks. An intervention implementation process evaluation is part of this study. Outcomes: The primary outcome is change in number of regional wall motion abnormalities (RWMAs) at peak hemodialysis stress from baseline to 12 weeks. Secondary outcomes include changes in cognitive function, hemodialysis recovery time, and symptom burden. Statistical Analysis: Change in number of RWMAs at peak hemodialysis stress from baseline to 12 weeks are compared between study groups using an independent 2-tailed t test and using a Poisson generalized linear mixed model with study group as a fixed effect, and time and mean ultrafiltration rate as random effects. Conclusion: Compared with standard care, we anticipate that intradialytic cycling will decrease myocardial stunning, resulting in improved symptom burden, and functional and cognitive status. This trial provides critical evidence regarding the benefits and feasibility of exercise during hemodialysis, potentially informing clinical practice, and guidelines for hemodialysis care. Trial registration number: NCT04877041
- Open Access
- 9 December 2025
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 12
Outcomes of Adopting a Higher Versus Lower Concentration of Hemodialysate Magnesium as a Center-Wide Policy (Dial-Mag): A Clinical Research Protocol of a Pragmatic, Registry-Based, Cluster Randomized Trial
Background: In individuals receiving hemodialysis, lower serum magnesium concentrations are associated with a higher risk of death and cardiovascular disease and more discomfort from muscle cramps. Small trials suggest that increasing serum magnesium by using a higher concentration of dialysate magnesium may be beneficial. This protocol outlines a large, randomized trial examining the effects of adopting a high versus low concentration of dialysate magnesium as a hemodialysis center-wide policy on the risk of mortality, major adverse cardiovascular events, and the burden of muscle cramps. Objective: To determine whether implementing a dialysate magnesium concentration of 0.75 mmol/L versus ≤ 0.5 mmol/L as a hemodialysis center-wide policy, for up to 4 years, affects (1) the rate of all-cause mortality or major cardiovascular-related hospitalizations or (2) the level of discomfort individuals experience from muscle cramps. Design: Pragmatic, 2-arm, parallel-group, registry-based, open-label, 2-sided superiority cluster randomized trial. Hemodialysis centers were randomly allocated (1:1) to one of the 2 arms. The assignment was constrained by five center-level prognostic factors and stratified by province. Setting: 137 hemodialysis centers in four Canadian provinces—Ontario, British Columbia, Alberta, and Manitoba. The trial period is from April 4, 2022, to March 31, 2026. Outcomes will be analyzed after March 31, 2026, using provincial health care databases and self-reported questionnaires. Participants: Individuals who received maintenance hemodialysis at participating centers during the trial period. Intervention: Use of a dialysate magnesium concentration of either 0.75 mmol/L or ≤ 0.5 mmol/L as a center-wide policy during the trial period. Measurements: The two primary outcomes are (1) a composite of all-cause mortality or major cardiovascular-related hospitalization (a hospital admission with myocardial infarction, congestive heart failure, or ischemic stroke) recorded in large health care databases and (2) self-reported muscle cramps collected from questionnaires. Methods: Using an intent-to-treat approach, the intervention effect on the instantaneous rate of the primary composite outcome will be analyzed using a stratified Cox proportional hazards model accounting for center-level clustering. The observation time will be censored for provincial emigration or the trial end date. Self-reported muscle cramps will be analyzed using a cumulative link (proportional odds) model. All models will be stratified by province and adjusted for the covariates used to constrain randomization. Limitations: The trial start date was delayed in some centers due to post-pandemic supply disruptions (including discontinued dialysate formulations); however, all centers secured dialysate concentrates in alignment with the trial-allocated magnesium level. Conclusions: The results of this pragmatic trial will inform center-wide policy on the optimal dialysate magnesium concentration for patient health. Trial Registration: www.clinicaltrials.gov ; identifier: NCT04079582
- 9 December 2025
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 12
Open AccessOutcomes of Adopting a Higher Versus Lower Concentration of Hemodialysate Magnesium as a Center-Wide Policy (Dial-Mag): A Clinical Research Protocol of a Pragmatic, Registry-Based, Cluster Randomized Trial
Background: In individuals receiving hemodialysis, lower serum magnesium concentrations are associated with a higher risk of death and cardiovascular disease and more discomfort from muscle cramps. Small trials suggest that increasing serum magnesium by using a higher concentration of dialysate magnesium may be beneficial. This protocol outlines a large, randomized trial examining the effects of adopting a high versus low concentration of dialysate magnesium as a hemodialysis center-wide policy on the risk of mortality, major adverse cardiovascular events, and the burden of muscle cramps. Objective: To determine whether implementing a dialysate magnesium concentration of 0.75 mmol/L versus ≤ 0.5 mmol/L as a hemodialysis center-wide policy, for up to 4 years, affects (1) the rate of all-cause mortality or major cardiovascular-related hospitalizations or (2) the level of discomfort individuals experience from muscle cramps. Design: Pragmatic, 2-arm, parallel-group, registry-based, open-label, 2-sided superiority cluster randomized trial. Hemodialysis centers were randomly allocated (1:1) to one of the 2 arms. The assignment was constrained by five center-level prognostic factors and stratified by province. Setting: 137 hemodialysis centers in four Canadian provinces—Ontario, British Columbia, Alberta, and Manitoba. The trial period is from April 4, 2022, to March 31, 2026. Outcomes will be analyzed after March 31, 2026, using provincial health care databases and self-reported questionnaires. Participants: Individuals who received maintenance hemodialysis at participating centers during the trial period. Intervention: Use of a dialysate magnesium concentration of either 0.75 mmol/L or ≤ 0.5 mmol/L as a center-wide policy during the trial period. Measurements: The two primary outcomes are (1) a composite of all-cause mortality or major cardiovascular-related hospitalization (a hospital admission with myocardial infarction, congestive heart failure, or ischemic stroke) recorded in large health care databases and (2) self-reported muscle cramps collected from questionnaires. Methods: Using an intent-to-treat approach, the intervention effect on the instantaneous rate of the primary composite outcome will be analyzed using a stratified Cox proportional hazards model accounting for center-level clustering. The observation time will be censored for provincial emigration or the trial end date. Self-reported muscle cramps will be analyzed using a cumulative link (proportional odds) model. All models will be stratified by province and adjusted for the covariates used to constrain randomization. Limitations: The trial start date was delayed in some centers due to post-pandemic supply disruptions (including discontinued dialysate formulations); however, all centers secured dialysate concentrates in alignment with the trial-allocated magnesium level. Conclusions: The results of this pragmatic trial will inform center-wide policy on the optimal dialysate magnesium concentration for patient health. Trial Registration: www.clinicaltrials.gov ; identifier: NCT04079582
- 2 June 2025
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 49 (5-6) , 325-332.e6
Association Between Insulin Regimen and Risk of Severe Hypoglycemia and Mortality in Adults With Type 2 Diabetes: A Large, Population-based, Retrospective Cohort Study
- 2 June 2025
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 49 (5-6) , 325-332.e6
Association Between Insulin Regimen and Risk of Severe Hypoglycemia and Mortality in Adults With Type 2 Diabetes: A Large, Population-based, Retrospective Cohort Study
- Open Access
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1510-1521
Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and 2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and 2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1510-1521
Open AccessSafety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and 2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and 2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.
- Open Access
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1482-1490
Predicting Postoperative Cardiac Events and Mortality for People with Kidney Failure Having Noncardiac Surgery
Key Points: Three models developed specifically for people with kidney failure were externally evaluated in a distinct Canadian province. All three models performed well, with some improvement with the re-estimation of predictor coefficients. Models have the potential to improve clinical decision making, and future research should evaluate their clinical effect. Background: Patients with kidney failure undergoing noncardiac surgery are at high risk of adverse cardiac events and mortality; however, existing perioperative risk prediction tools for these outcomes are not valid in these patients. Recently, three models were developed from a kidney failure cohort in Alberta, Canada. In this study, we evaluated these Alberta models in a kidney failure cohort that had surgery in Manitoba, Canada. Methods: The cohort included adults from Manitoba, Canada (18 years or older), with preexisting kidney failure (eGFR 2 or receiving maintenance dialysis) undergoing noncardiac surgeries between 2007 and 2019. The primary outcome was a composite of acute myocardial infarction, cardiac arrest, ventricular arrhythmia, and all-cause mortality within 30 days. The three models included an increasing number of variables: demographics and surgical characteristics (model 1), comorbidities (model 2), and preoperative albumin and hemoglobin (model 3). Model performance was evaluated using area under the receiver operating characteristic curve (AUC-ROC), calibration, and Brier score on Manitoba data. This was evaluated by applying Alberta model coefficients for all three models to predict outcomes on Manitoba data and also by re-estimating the Alberta model predictor coefficients using logistic regression on Manitoba data. Results: We identified 12,082 surgeries performed in 4175 participants; 569 outcomes were observed (4.7%). All three models performed well with both approaches, with AUC-ROC ranging from 0.821 (model 1) to 0.874 (model 3) using the models with Alberta coefficients. Calibration slopes were 1.32, 1.40, and 1.24 for models 1, 2, and 3, respectively. On refitting, AUC-ROC ranged from 0.830 (model 1) to 0.861 (model 3). Calibration slopes approximated one across all the re-estimated models. Brier scores remained <0.1 across all original and re-estimated models. Conclusions: Our external validation study confirmed that the kidney failure specific postoperative outcome models developed in Alberta, Canada, performed well in a geographically distinct Canadian population. Future research should explore the performance of these models in different settings and evaluate their clinical effect with prospective implementation.
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1482-1490
Open AccessPredicting Postoperative Cardiac Events and Mortality for People with Kidney Failure Having Noncardiac Surgery
Key Points: Three models developed specifically for people with kidney failure were externally evaluated in a distinct Canadian province. All three models performed well, with some improvement with the re-estimation of predictor coefficients. Models have the potential to improve clinical decision making, and future research should evaluate their clinical effect. Background: Patients with kidney failure undergoing noncardiac surgery are at high risk of adverse cardiac events and mortality; however, existing perioperative risk prediction tools for these outcomes are not valid in these patients. Recently, three models were developed from a kidney failure cohort in Alberta, Canada. In this study, we evaluated these Alberta models in a kidney failure cohort that had surgery in Manitoba, Canada. Methods: The cohort included adults from Manitoba, Canada (18 years or older), with preexisting kidney failure (eGFR 2 or receiving maintenance dialysis) undergoing noncardiac surgeries between 2007 and 2019. The primary outcome was a composite of acute myocardial infarction, cardiac arrest, ventricular arrhythmia, and all-cause mortality within 30 days. The three models included an increasing number of variables: demographics and surgical characteristics (model 1), comorbidities (model 2), and preoperative albumin and hemoglobin (model 3). Model performance was evaluated using area under the receiver operating characteristic curve (AUC-ROC), calibration, and Brier score on Manitoba data. This was evaluated by applying Alberta model coefficients for all three models to predict outcomes on Manitoba data and also by re-estimating the Alberta model predictor coefficients using logistic regression on Manitoba data. Results: We identified 12,082 surgeries performed in 4175 participants; 569 outcomes were observed (4.7%). All three models performed well with both approaches, with AUC-ROC ranging from 0.821 (model 1) to 0.874 (model 3) using the models with Alberta coefficients. Calibration slopes were 1.32, 1.40, and 1.24 for models 1, 2, and 3, respectively. On refitting, AUC-ROC ranged from 0.830 (model 1) to 0.861 (model 3). Calibration slopes approximated one across all the re-estimated models. Brier scores remained <0.1 across all original and re-estimated models. Conclusions: Our external validation study confirmed that the kidney failure specific postoperative outcome models developed in Alberta, Canada, performed well in a geographically distinct Canadian population. Future research should explore the performance of these models in different settings and evaluate their clinical effect with prospective implementation.
- 1 January 2025
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 50, 1-11
Evaluation of an online cardiometabolic and weight loss program: a mixed methods study
Risk factors contributing to cardiovascular diseases (CVD) can be addressed through behavior modification, including changes in diet and physical activity. In 2021, The Wellness Institute (WI), located at Seven Oaks General Hospital, created a virtual cardiometabolic risk reduction program in response to COVID-19 pandemic public health restrictions, encompassing virtual health coaching and lifestyle education. The objective was to evaluate the acceptability, adherence, efficacy, and engagement of the WI online cardiometabolic and weight loss program. The study followed a mixed methods quasi-experimental design. A total of 93 participants enrolled. Quantitative measures including anthropometrics, blood chemistry, and lifestyle were assessed for changes via paired t tests at baseline and 16 weeks. Qualitatively, short answer questionnaires and three focus groups were completed to understand participants’ experiences and program acceptability. We combined qualitative and quantitative data for analysis. Seventy-three participants (64 females, 87.7%) completed the final study visit (age 58 ± 11 years, weight 98 ± 20.9 kg). Of those, 98% attended all coaching sessions, would recommend the program, and reported the coaching sessions helped them stay motivated. A reduction in weight (5 ± 9 kg, p < 0.001), systolic blood pressure (6 ± 10 mmHg, p < 0.001), and diastolic blood pressure (4 ± 8 mmHg, p < 0.001) were observed. Lifestyle factors also improved, including increases in physical activity ( p < 0.05). Most participants adhered to the program and found it acceptable. Completion was associated with an improvement in weight and blood pressure. These findings highlight the potential of virtual programming to contribute to improving lifestyle and health. Clinicaltrials.gov (ID# NCT04784624CT).
- 1 January 2025
- Published by Canadian Science Publishing in Applied Physiology, Nutrition, and Metabolism
- Vol. 50, 1-11
Evaluation of an online cardiometabolic and weight loss program: a mixed methods study
Risk factors contributing to cardiovascular diseases (CVD) can be addressed through behavior modification, including changes in diet and physical activity. In 2021, The Wellness Institute (WI), located at Seven Oaks General Hospital, created a virtual cardiometabolic risk reduction program in response to COVID-19 pandemic public health restrictions, encompassing virtual health coaching and lifestyle education. The objective was to evaluate the acceptability, adherence, efficacy, and engagement of the WI online cardiometabolic and weight loss program. The study followed a mixed methods quasi-experimental design. A total of 93 participants enrolled. Quantitative measures including anthropometrics, blood chemistry, and lifestyle were assessed for changes via paired t tests at baseline and 16 weeks. Qualitatively, short answer questionnaires and three focus groups were completed to understand participants’ experiences and program acceptability. We combined qualitative and quantitative data for analysis. Seventy-three participants (64 females, 87.7%) completed the final study visit (age 58 ± 11 years, weight 98 ± 20.9 kg). Of those, 98% attended all coaching sessions, would recommend the program, and reported the coaching sessions helped them stay motivated. A reduction in weight (5 ± 9 kg, p < 0.001), systolic blood pressure (6 ± 10 mmHg, p < 0.001), and diastolic blood pressure (4 ± 8 mmHg, p < 0.001) were observed. Lifestyle factors also improved, including increases in physical activity ( p < 0.05). Most participants adhered to the program and found it acceptable. Completion was associated with an improvement in weight and blood pressure. These findings highlight the potential of virtual programming to contribute to improving lifestyle and health. Clinicaltrials.gov (ID# NCT04784624CT).